ArticleResearch and practice in thrombosis and haemostasis2025
The absence of standardization in antiphospholipid antibody testing may favor the use of 99th percentile cutoffs in antiphospholipid syndrome classification.
Article in Research and practice in thrombosis and haemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Antiphospholipid antibodies and cardiovascular thrombosis.Nature reviews. Cardiology · 2026Review
- Population-specific antiphospholipid antibody titres in a South Indian cohort: defining cut-off values and implications for diagnosis from a cross-sectional validation study.BMC rheumatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Classification criteria for antiphospholipid syndrome (APS) issued by the American College of Rheumatology/European Alliance of Associations for Rhuematology necessitate a positivity for any of the 3 molecular targets: lupus anticoagulant, anticardiolipin (aCL) immunoglobulin G, or anti-β2 glycoprotein I (aβ2GPI) immunoglobulin G, with the latter 2 requiring concentrations > 40 units. This specification implies having standardized and comparable calibration strategies to achieve proper patient classification. In the past, calibrator tests suffered from poor standardization; thus, the 99th percentile was established as the cutoff point. Objectives: We aimed to find a balance between sensitivity and specificity in the laboratory criteria for patient enrollment in APS studies by harmonizing the 99th percentile and 40-unit threshold. Methods: In a cohort of 250 healthy individuals, we tested aCL and aβ2GPI concentrations by 4 different methods: 3 colorimetric, standardized ELISA platforms and 1 chemiluminescence assay, to define the 99th percentile. We tested cross-reactivity of standardized calibrators between kits and how to implement better accuracy for patient enrollment in a cohort of 80 APS patients. Results: We found that the 99th percentile was substantially <40-unit cutoff and observed considerable interkit variability in the determined cutoffs, which originated from the inadequate standardization of kit calibrators. In a second cohort of 80 APS patients, we estimated the accuracy of these different methods by comparing the 99th percentile and 40-unit cutoffs. For certain ELISA kits, using a fixed cutoff of 40 units instead of the 99th percentile decreased their sensitivity without increasing specificity, which affected patient classification and thus the number of patients eligible for APS studies. Testing with 2 ELISA platforms at the 99th percentile cutoff would improve patient eligibility. Conclusion: Our survey suggests that in the absence of standardized calibrators for testing aCL or aβ2GPI, a cutoff point at the 99th percentile of 2 different ELISA kits should be adopted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.